trial
as of 2026-07-01Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
NCTId NCT02533232
at a glance
Phase 1 · Unknown
Enrollment 60 (estimated)
Sponsored by Pakistan Institute of Living and Learning
Primary completion 2022-12-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Unknown
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-08-30
Primary completion
2022-12-30
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Pakistan Institute of Living and LearningLead Sponsor
Investigators
1
Dr.Inti Qurashi, MDPrincipal Investigator
Sites
4 total
Karachi, PakistanKarachi, PakistanKarachi, PakistanKarachi, Pakistan
Facts & assertions
4 sourced
Enrollment
60
Phase
PHASE1
Primary Completion Date
2022-12-30
Status
UNKNOWN
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person